Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).
1 finding from 1 review
Adverse event · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
1 finding from 1 review
Reduction in pain intensity · people with acute soft tissue injury, such as ankle sprain
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · acute soft tissue injury
1 finding from 1 review
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · acute soft tissue injury
1 finding from 1 review
Little or no swelling on day 7 or later · acute soft tissue injury
It is very uncertain whether NSAID changes little or no swelling on day 7 or later compared with opioid (very low certainty).
1 finding from 1 review
Return to function on day 7 or later (numbers returning to full function or returning to training) · acute soft tissue injury
NSAID may leads to higher return to function on day 7 or later (numbers returning to full… compared with opioid (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · acute soft tissue injury
NSAID probably leads to lower gastrointestinal adverse events compared with opioid (moderate certainty).
1 finding from 1 review
Neurological adverse effects · acute soft tissue injury
NSAID probably leads to lower neurological adverse events compared with opioid (moderate certainty).
1 finding from 1 review
Early re‐injury (with 3 months) · acute soft tissue injury
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Little or no pain at < 24 hours · people with acute soft tissue injury, such as ankle sprain
1 finding from 1 review
Little or no pain at 1 to 3 days · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes little or no pain at 1 to 3 days compared with combination (paracetamol and opioid) analgesic (very low certainty).
2 findings from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with acute soft tissue injury, such as ankle sprain
1 finding from 1 review
Swelling (7th day) · people with acute soft tissue injury, such as ankle sprain
1 finding from 1 review
Return to function on day 7 or later Assessed as 'cure' · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes return to function on day 7 or later Assessed as 'cure' compared with combination (paracetamol and opioid) analgesic (very low certainty).
1 finding from 1 review